Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Liabilities (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Total Liabilities for 7 consecutive years, with $34.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 21.3% year-over-year to $34.9 million, compared with a TTM value of $34.9 million through Dec 2025, down 21.3%, and an annual FY2025 reading of $34.9 million, down 21.3% over the prior year.
  • Total Liabilities was $34.9 million for Q4 2025 at Keros Therapeutics, down from $39.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $55.7 million in Q1 2025 and bottomed at -$453.9 million in Q1 2024.
  • Average Total Liabilities over 5 years is -$13.4 million, with a median of $29.4 million recorded in 2022.
  • Peak annual rise in Total Liabilities hit 163.82% in 2023, while the deepest fall reached 2211.31% in 2023.
  • Year by year, Total Liabilities stood at $12.1 million in 2021, then skyrocketed by 143.09% to $29.4 million in 2022, then rose by 28.8% to $37.8 million in 2023, then grew by 17.25% to $44.3 million in 2024, then dropped by 21.3% to $34.9 million in 2025.
  • Business Quant data shows Total Liabilities for KROS at $34.9 million in Q4 2025, $39.2 million in Q3 2025, and $50.4 million in Q2 2025.